CA2426959C - Animaux transgeniques utilises pour analyser la regulation du gene p450 du cytochrome cyp3a4 - Google Patents
Animaux transgeniques utilises pour analyser la regulation du gene p450 du cytochrome cyp3a4 Download PDFInfo
- Publication number
- CA2426959C CA2426959C CA2426959A CA2426959A CA2426959C CA 2426959 C CA2426959 C CA 2426959C CA 2426959 A CA2426959 A CA 2426959A CA 2426959 A CA2426959 A CA 2426959A CA 2426959 C CA2426959 C CA 2426959C
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- acid molecule
- reporter
- human
- transcription
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 title claims description 24
- 241001465754 Metazoa Species 0.000 title abstract description 16
- 230000009261 transgenic effect Effects 0.000 title abstract description 10
- 230000033228 biological regulation Effects 0.000 title abstract description 7
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 104
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 104
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 104
- 230000001105 regulatory effect Effects 0.000 claims abstract description 82
- 241000282414 Homo sapiens Species 0.000 claims abstract description 65
- 230000035897 transcription Effects 0.000 claims abstract description 55
- 238000013518 transcription Methods 0.000 claims abstract description 55
- 230000014509 gene expression Effects 0.000 claims abstract description 53
- 239000002773 nucleotide Substances 0.000 claims abstract description 46
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 46
- 101150116544 CYP3A4 gene Proteins 0.000 claims abstract description 43
- 239000002676 xenobiotic agent Substances 0.000 claims abstract description 39
- 101000745711 Homo sapiens Cytochrome P450 3A4 Proteins 0.000 claims abstract description 35
- 230000002034 xenobiotic effect Effects 0.000 claims abstract description 31
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 26
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 22
- 230000000977 initiatory effect Effects 0.000 claims abstract description 19
- -1 but not exclusively Chemical class 0.000 claims abstract description 7
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 17
- 230000037425 regulation of transcription Effects 0.000 claims description 11
- 108700009124 Transcription Initiation Site Proteins 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 8
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims description 8
- 102000034527 Retinoid X Receptors Human genes 0.000 claims description 8
- 108010038912 Retinoid X Receptors Proteins 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 102000006255 nuclear receptors Human genes 0.000 claims description 8
- 108020004017 nuclear receptors Proteins 0.000 claims description 8
- 102000040945 Transcription factor Human genes 0.000 claims description 6
- 108091023040 Transcription factor Proteins 0.000 claims description 6
- QZLYKIGBANMMBK-UGCZWRCOSA-N 5α-Androstane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 QZLYKIGBANMMBK-UGCZWRCOSA-N 0.000 claims description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 4
- 108090000331 Firefly luciferases Proteins 0.000 claims description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 4
- 239000005090 green fluorescent protein Substances 0.000 claims description 4
- 239000000833 heterodimer Substances 0.000 claims description 4
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 claims description 3
- 101000603877 Homo sapiens Nuclear receptor subfamily 1 group I member 2 Proteins 0.000 claims description 2
- 102000046617 human NR1I2 Human genes 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 108020002494 acetyltransferase Proteins 0.000 claims 1
- 102000005421 acetyltransferase Human genes 0.000 claims 1
- 210000001082 somatic cell Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 230000002103 transcriptional effect Effects 0.000 abstract description 3
- 108700019146 Transgenes Proteins 0.000 description 41
- 210000001519 tissue Anatomy 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 18
- 230000006698 induction Effects 0.000 description 17
- 101150066555 lacZ gene Proteins 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 13
- 229960003957 dexamethasone Drugs 0.000 description 12
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 108020005029 5' Flanking Region Proteins 0.000 description 10
- 102100038494 Nuclear receptor subfamily 1 group I member 2 Human genes 0.000 description 9
- 108010001511 Pregnane X Receptor Proteins 0.000 description 9
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 229960000249 pregnenolone Drugs 0.000 description 9
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 description 9
- 238000010171 animal model Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 7
- 229960001225 rifampicin Drugs 0.000 description 7
- 150000003431 steroids Chemical class 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 101100187477 Homo sapiens NR1I2 gene Proteins 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 238000009509 drug development Methods 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 102100038512 Nuclear receptor subfamily 1 group I member 3 Human genes 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 3
- 229960002695 phenobarbital Drugs 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 101150061952 CYP3A7 gene Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 description 2
- 101000745715 Homo sapiens Cytochrome P450 3A7 Proteins 0.000 description 2
- 101000603882 Homo sapiens Nuclear receptor subfamily 1 group I member 3 Proteins 0.000 description 2
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 2
- 229960004022 clotrimazole Drugs 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 229960004833 dexamethasone phosphate Drugs 0.000 description 2
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 2
- 230000008406 drug-drug interaction Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 229960002036 phenytoin Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- GHKCSRZBNZQHKW-UWTATZPHSA-N (1R)-1-sulfanylethanol Chemical compound C[C@H](O)S GHKCSRZBNZQHKW-UWTATZPHSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000043966 ABC-type transporter activity proteins Human genes 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102100039203 Cytochrome P450 3A7 Human genes 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- 101150066553 MDR1 gene Proteins 0.000 description 1
- 101100114688 Mus musculus Cyp3a11 gene Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150053185 P450 gene Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 230000009716 hepatic expression Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000053576 human ABCB1 Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 239000000276 potassium ferrocyanide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Environmental Sciences (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La présente invention concerne la génération d'animaux transgéniques non humains comprenant une construction de rapporteur en vue de produire une quantité détectable d'une molécule rapporteur fonctionnellement liée à une molécule d'acide nucléique de régulation transcriptionnelle provenant du gène humain CYP3A4 situé entre le début du site de transcription du gène et un endroit situé 13 000 nucléotides en amont du site. Cette invention concerne également l'utilisation de ces animaux pour déterminer l'effet d'un composé, notamment mais pas uniquement, d'un xénobiotique ou d'un stéroïde, sur la régulation de l'expression du gène CYP3A4 chez l'homme.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR1161A AUPR116100A0 (en) | 2000-11-01 | 2000-11-01 | P450 gene regulation |
| AUPR1161 | 2000-11-01 | ||
| AUPR4901 | 2001-05-10 | ||
| AUPR4901A AUPR490101A0 (en) | 2001-05-10 | 2001-05-10 | P450 gene regulation ii |
| PCT/AU2001/001407 WO2002036784A1 (fr) | 2000-11-01 | 2001-11-01 | Animaux transgeniques utilises pour analyser la regulation du gene p450 du cytochrome cyp3a4 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2426959A1 CA2426959A1 (fr) | 2002-05-10 |
| CA2426959C true CA2426959C (fr) | 2011-10-04 |
Family
ID=27664007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2426959A Expired - Fee Related CA2426959C (fr) | 2000-11-01 | 2001-11-01 | Animaux transgeniques utilises pour analyser la regulation du gene p450 du cytochrome cyp3a4 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1337650A4 (fr) |
| JP (2) | JP2004512054A (fr) |
| AU (2) | AU2002213660A1 (fr) |
| CA (1) | CA2426959C (fr) |
| WO (1) | WO2002036784A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP362898A0 (en) | 1998-05-21 | 1998-06-11 | University Of Sydney, The | Xenobiotic induction of gene expression |
| AUPR116100A0 (en) | 2000-11-01 | 2000-11-23 | University Of Sydney, The | P450 gene regulation |
| JP2005510205A (ja) * | 2001-04-12 | 2005-04-21 | ゼノジェン コーポレイション | チトクロム発現に関連するマウスおよびヒト転写制御エレメントの単離および同定 |
| US7700822B2 (en) | 2002-07-12 | 2010-04-20 | Cancer Research Technology Limited | Modulation of cytochrome P450 reductase activity |
| GB0216203D0 (en) * | 2002-07-12 | 2002-08-21 | Imp Cancer Res Tech | Mondulation of cytochrome P450 reductase activity |
| US7759541B2 (en) | 2004-12-13 | 2010-07-20 | Iti Life Sciences | Transgenic animals for assessing drug metabolism and toxicity |
| WO2006064197A2 (fr) * | 2004-12-13 | 2006-06-22 | Iti Scotland Limited | Animaux transgeniques pour evaluer le metabolisme et la toxicite d'un medicament |
| KR100811184B1 (ko) * | 2005-10-21 | 2008-03-07 | 삼성전자주식회사 | 아우터 인코더 및 그 방법 |
| JP6315478B2 (ja) | 2012-10-19 | 2018-04-25 | 国立大学法人鳥取大学 | 薬物代謝酵素誘導および細胞毒性の評価方法、ならびにそのためのベクターおよび細胞 |
| JP6868237B2 (ja) * | 2016-10-11 | 2021-05-12 | 国立大学法人鳥取大学 | ヒトの薬物代謝酵素誘導及び薬物動態予測が可能な新規薬物代謝酵素誘導評価方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002535241A (ja) * | 1998-03-27 | 2002-10-22 | グラクソ グループ リミテッド | オーファン核内受容体 |
| AUPP362898A0 (en) * | 1998-05-21 | 1998-06-11 | University Of Sydney, The | Xenobiotic induction of gene expression |
| US20020168623A1 (en) * | 2000-04-12 | 2002-11-14 | Judy Raucy | Compositions and methods for induction of proteins involved in xenobiotic metabolism |
| JP2005510205A (ja) * | 2001-04-12 | 2005-04-21 | ゼノジェン コーポレイション | チトクロム発現に関連するマウスおよびヒト転写制御エレメントの単離および同定 |
-
2001
- 2001-11-01 CA CA2426959A patent/CA2426959C/fr not_active Expired - Fee Related
- 2001-11-01 EP EP01981959A patent/EP1337650A4/fr not_active Withdrawn
- 2001-11-01 JP JP2002539530A patent/JP2004512054A/ja active Pending
- 2001-11-01 WO PCT/AU2001/001407 patent/WO2002036784A1/fr not_active Ceased
- 2001-11-01 AU AU2002213660A patent/AU2002213660A1/en not_active Abandoned
-
2007
- 2007-12-18 AU AU2007249083A patent/AU2007249083B8/en not_active Ceased
-
2009
- 2009-12-28 JP JP2009297935A patent/JP5543771B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007249083B2 (en) | 2010-12-16 |
| AU2007249083B8 (en) | 2011-02-03 |
| EP1337650A1 (fr) | 2003-08-27 |
| CA2426959A1 (fr) | 2002-05-10 |
| WO2002036784A1 (fr) | 2002-05-10 |
| JP2010148508A (ja) | 2010-07-08 |
| JP2004512054A (ja) | 2004-04-22 |
| JP5543771B2 (ja) | 2014-07-09 |
| EP1337650A4 (fr) | 2005-12-21 |
| AU2002213660A1 (en) | 2002-05-15 |
| AU2007249083A1 (en) | 2008-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007249083B8 (en) | Transgenic animals for analysing CYP3A4 cytochrome P450 gene regulation | |
| Gow et al. | Myelin basic protein gene contains separate enhancers for oligodendrocyte and Schwann cell expression. | |
| Burdon et al. | Expression of a whey acidic protein transgene during mammary development. Evidence for different mechanisms of regulation during pregnancy and lactation. | |
| Donohoe et al. | Targeted disruption of mouse Yin Yang 1 transcription factor results in peri-implantation lethality | |
| AU683227B2 (en) | Tetracycline repressor-mediated binary regulation system for control of gene expression in transgenic animals | |
| CA1321764C (fr) | Sequence d'adn utilisee pour concentrer la synthese de certaines proteines dans la glande mammaire afin de rendre la secretion plus efficace | |
| US5709844A (en) | Transgenic mice expressing HPV early region oncogene develop progressive cervico-vaginal neoplasia | |
| US5583009A (en) | Method of preparing recombinant proteins in transgenic animals containing metallothionein gene elements that bestow tissue-independent copy number-dependent, position-indepedent gene expression | |
| Michicich et al. | A W1282X cystic fibrosis mouse allows the study of pharmacological and gene-editing therapeutics to restore CFTR function | |
| Adrian et al. | Human transferrin. Expression and iron modulation of chimeric genes in transgenic mice. | |
| US8088968B2 (en) | Transgenic animals for analyzing CYP3A4 cytochrome P450 gene regulation | |
| AU2002318920B2 (en) | Animal model for fatty acid amide-related neurobehaviors | |
| Pawlik et al. | Autonomous, erythroid-specific DNase I hypersensitive site formed by human β-globin locus control region (LCR) 5′ HS 2 in transgenic mice | |
| DE69428319T2 (de) | Genomische DNS für menschliche Cholesterol-7-alpha Hydroxylase und Verfahren zu dessen Verwendung | |
| AU2002318920A1 (en) | Animal model for fatty acid amide-related neurobehaviors | |
| Asante et al. | Tissue specific expression of an α-skeletal actin-lacZ fusion gene during development in transgenic mice | |
| Wagner et al. | The renin-angiotensin system in transgenic rats | |
| EP1743523A1 (fr) | Animal transgénique non humain en tant que modèle pour le diabète de type 2 | |
| Thomas Jr | DNA determinants of the androgen response of mouse beta-glucuronidase | |
| WO2006085673A1 (fr) | Animal transgenique sans poils | |
| Sinn | Transgenic models and molecular mechanisms of human renin gene regulation | |
| Ting | Endogenous retroviral sequences regulate tissue-specific expression of a human salivary amylase gene in transgenic mice | |
| JP2003169679A (ja) | ヒトβ３受容体発現動物 | |
| US20020023276A1 (en) | Dna sequences to target proteins to the mammary gland for efficient secretion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20171101 |